Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glumetinib plus HB1801 in MET-overexpressed NSCLC
NCT06525350Phase 2Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Nanoparticles, Allosteric Modulators
01
Overview
Phase 2, randomised, open-label trial of glumetinib and albumin-bound docetaxel in non-small cell lung cancer (NSCLC) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose-limiting toxicity up to 48 months, Recommended Phase 2 Dose up to 48 months and 2 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
glumetinibalbumin-bound docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06525350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525350.